Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities
Net loss	$ (2,571,507)	$ (4,261,684)
Adjustments to reconcile net loss to net cash used in operating activities:
Research and development-acquired license, expensed	25,000	62,545
Stock-based compensation	577,438	1,126,038
Realized loss on marketable securities		(33,330)
Unrealized loss (gain) on marketable securities	(21,949)	17,930
Changes in operating assets and liabilities:
Prepaid expenses	(92,556)	(88,020)
Accounts payable	(52,915)	453,930
Net cash used in operating activities	(2,136,489)	(2,722,591)
Cash flows from investing activities
Purchase of research and development licenses	(25,000)	(69,545)
Sale of marketable securities		1,026,755
Net cash (used in) provided by investing activities	(25,000)	957,210
Cash flows from financing activities
Proceeds from issuance common stock, common stock warrants and prefunded warrants, net of offering cost		13,507,632
Proceeds from issuance common stock and warrants, net of offering cost		4,565,001
Proceeds from exercise of warrants		358,745
Net cash provided by financing activities		18,431,378
Effect of exchange rate changes on cash and cash equivalents	4,001	6,474
Net change in cash	(2,161,489)	16,665,997
Cash, beginning of period	8,538,270	2,629,670
Cash, end of period	$ 6,380,782	$ 19,302,141